Serum Institute CEO says vaccine development is like rollercoaster

Published On 2020-05-23 03:45 GMT   |   Update On 2020-05-23 03:46 GMT

New Delhi: Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that developing a vaccine is like a rollercoaster ride with ups and downs. "Developing a vaccine is like riding a rollercoaster; there are plenty of ups and downs. Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to...

Login or Register to read the full article

New Delhi: Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that developing a vaccine is like a rollercoaster ride with ups and downs.

"Developing a vaccine is like riding a rollercoaster; there are plenty of ups and downs. Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed," Poonawalla said in a tweet.

There have been reports that one of the strong candidates for a potential vaccine for Covid-19 being tested by researchers at the Oxford University has failed to protect monkeys from being infected by the virus. However, the potential vaccine helped to protect the monkeys from pneumonia.

Reports of the Oxford vaccine's performance on monkeys had prompted researchers to test the vaccine's potency in humans.

The potential of the vaccine had also led to the Serum Institute announcing plans to manufacture four to five million doses in India. It is one of seven global companies that will manufacture the vaccine being developed by the Oxford Vaccine Group.

Read also: AstraZeneca receives 1 Billion USD investment for Oxford vaccine


Tags:    
Article Source : IANS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Disclaimer :- This story, apart from the heading, has not been edited by Medical Dialogues Team and is auto-generated from news agency feeds. Source: IANS

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News